Researchers analyzed 10 matched pairs of primary cultures, with each pair derived from a prostate tumor and non-tumor tissue collected from the same patient. The patients had Gleason grades of 7, preoperative prostate-specific antigen levels ranging from 3.4 to 13 nanograms per milliliter, and pathologic stages from T2 to T3. Six tumors were classified as organ-confined, while four showed extraprostatic extension.

The paired design allowed investigators to identify somatic alterations using each patient’s non-malignant cells as a reference for subtracting germline variation and sequencing artifacts. The epithelial cultures were expanded through conditional reprogramming before sequencing. To limit interference from the mouse fibroblast feeder layer used during culture, investigators separately aligned reads to human and mouse reference genomes, removed reads with stronger or similar mouse alignment scores, and used additional checks to identify residual mouse sequence among candidate variants.

Whole-genome sequencing was performed with Illumina paired-end reads, and sequencing outputs passed quality-control thresholds of at least 110 gigabases, approximately 30-fold mean coverage and at least 95% coverage at 10-fold depth. Somatic variants were called with GATK MuTect2 using each matched non-tumor sample as the germline control, then annotated and evaluated for predicted functional impact. Tumor mutational burden was defined as nonsynonymous somatic mutations per megabase of the coding genome.

Mutations were distributed unevenly across the cohort, with clusters on chromosomes 1, 2, 3, 11, 17 and X. After counts were normalized by chromosome length, chromosome 17 had the highest mutation density, followed by chromosome 19. Tumor mutational burden ranged from 0.73 mutations per megabase in sample AP44 to 46.37 mutations per megabase in AP9, demonstrating substantial variation among the 10 patient models.

The analysis also identified evidence of genomic instability. Chromothripsis was defined through patterns including mutation clusters within individual chromosomes, complex rearrangements and oscillating copy-number states, while kataegis was identified from localized hypermutation near rearrangement breakpoints, including C-to-T or C-to-G substitutions in cytosine-rich motifs. Copy-number alterations were prominent on chromosomes 1 and 2 among the four samples represented in the copy-number heatmap. These findings characterize the analyzed cultures and do not establish clinical effects.

Alterations affecting chromatin remodeling and epigenetic regulation were among the most frequent findings. Reported mutation frequencies were 31.6% for KDM6A, 21.1% for ATRX, 7.9% for ARID1A and 5.3% for CHD1. DNA-damage-response genes also showed recurrent alterations: ATM occurred in 10.5% of samples, BRCA2 in 7.9%, BRCA1 in 5.3% and RAD51 in 2.6%. Pathway mapping placed the prioritized alterations on axes including PI3K/AKT/mTOR, Wnt signaling and androgen receptor pathways.

Functional-impact scoring and pathway analysis prioritized shared variants in genes including ATM and CDK12, while also identifying sample-specific candidates. One example was a candidate FOXA1-SSTR1 event comprising a missense variant in FOXA1 and an adjacent structural rearrangement involving SSTR1. The investigators also compared the cohort with predominantly European-ancestry genomic datasets and reported candidate mutations not represented in those references. Because the sample was small, the distinctness and therapeutic relevance of these candidates remain exploratory.

Genotype-phenotype analyses did not find statistically significant associations between tumor mutational burden and preoperative prostate-specific antigen, Gleason grade group or pathologic stage. The copy-number analysis included only four patients, and its associations with prostate-specific antigen and grade group were also non-significant. The investigators therefore described the findings as hypothesis-generating and called for validation in larger independent cohorts. The study did not report patient treatment, clinical outcomes, response to targeted drugs or evidence that any identified alteration produced a clinical benefit.

The principal limitations were the small, exclusively African American cohort of 10 patients, which was not designed to establish population-level mutation frequencies, and the use of conditionally reprogrammed cultures as experimental models rather than a direct survey of every cell in each tumor. Within those bounds, the paired cell models provide a renewable resource for functional testing of candidate variants and preclinical studies. The results support further investigation of ancestry-informed genomic profiling in larger, independent cohorts rather than treatment conclusions based on this discovery cohort.

Subject of Research: Whole-genome characterization of prostate cancer genomic alterations in paired primary cultures from African American men

Article Title: Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities

Article References: Murthy, S., Fago, K., Knight, J., Kowalczyk, K., Hankins, R., Bandi, G., Dritschilo, A., & Jung, M. (2026). Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities. PLOS One, 21(10), e0360389. https://doi.org/10.1371/journal.pone.0360389

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360389

Keywords: prostate cancer, African American men, whole-genome sequencing, paired primary cultures, somatic mutations, genomic instability, DNA damage response, chromatin remodeling, precision oncology, tumor mutational burden, Personalized, genomic

The study included 126 patients with muscle-invasive bladder cancer who underwent radical cystectomy with a Bricker ileal conduit, a urinary diversion technique in which a segment of intestine is used to create a stoma. Sixty-three patients were managed with a 22-element ERAS protocol adapted from ERAS Society guidelines, while 63 historical controls received standard perioperative care. The ERAS pathway combined eight preoperative elements, including patient education, nutritional optimization, carbohydrate loading, and shortened fasting, with seven intraoperative measures such as epidural analgesia, goal-directed fluid therapy, and active maintenance of body temperature, and seven postoperative elements including early feeding, early mobilization, and milestone-based discharge criteria. Many of these components were delivered or coordinated by nursing staff, making the protocol as much a nursing intervention as a surgical one.

To track immune changes, the team drew blood at three standardized timepoints: 24 hours before surgery, 24 hours after surgery, and on postoperative day seven or at discharge. Multiplex flow cytometry quantified cytotoxic CD8-positive T cells, regulatory T cells, and natural killer cells, while a 37-analyte Luminex panel measured inflammatory cytokines and ELISA assays captured soluble immune checkpoint molecules such as soluble PD-L1. The differences between the two groups were striking. In the ERAS cohort, CD8-positive T-cell counts fell by 22.8 percent from baseline in the first 24 hours after surgery, compared with a 41.6 percent decline in the conventional group, a difference that was highly statistically significant. Serum interleukin-6, a key inflammatory cytokine released during surgical stress, averaged 43.2 picograms per milliliter in ERAS patients versus 87.4 picograms per milliliter in conventional patients.

Beyond the cellular counts, the soluble immune landscape also differed. ERAS patients showed lower concentrations of soluble PD-L1 and soluble TIM-3, molecules shed into the bloodstream that are thought to dampen antitumor immunity, and higher levels of interferon-gamma, a cytokine central to cytotoxic immune defense. Natural killer cell activity was also better preserved, at 42.3 percent versus 31.7 percent. By postoperative day seven, several of these measures remained more favorable in the ERAS group, including higher CD8 counts and lower proportions of immunosuppressive regulatory T cells. The authors are careful to note, however, that these timepoint comparisons alone cannot establish a causal effect of ERAS on immune trajectories, since no formal group-by-time mixed-effects analysis was performed.

One of the most intriguing findings is an exploratory four-marker immune index measured 24 hours after surgery, combining CD8-positive T-cell count, interleukin-6, soluble PD-L1, and natural killer cell activity. When the researchers tested this composite score against the risk of infectious complications within 30 days of surgery, it achieved an area under the receiver operating characteristic curve of 0.84, with a 95 percent confidence interval of 0.76 to 0.92. That performance substantially exceeded a reference model based only on ASA score and clinical stage, which reached an AUC of 0.61. Individual markers performed less well, with interleukin-6 alone at 0.76 and CD8 count alone at 0.73, suggesting that the integration of multiple immune dimensions carries the predictive signal.

The team also examined the tumors themselves. Using multiplex immunofluorescence on surgical specimens, they quantified immune cell infiltration in tumor nests, invasive margins, and surrounding stroma. Specimens from the ERAS cohort showed higher densities of CD8-positive tumor-infiltrating lymphocytes in both tumor nests and invasive margins, lower densities of CD68-positive CD163-positive M2-polarized macrophages, and higher ratios of CD8-positive to FoxP3-positive cells, a measure that weighs cytotoxic against regulatory immune activity. Spatial transcriptomics performed on 24 specimens revealed higher expression of cytotoxic effector genes such as GZMB, PRF1, and IFNG, and lower expression of exhaustion markers including TIGIT, LAG3, and PDCD1 in the ERAS group. The immune-inflamed tumor phenotype, characterized by T cells penetrating deep into tumor tissue, was present in 52.4 percent of ERAS specimens versus 28.6 percent of conventional ones.

Here the authors issue an important caution. Because tumor tissue was collected at the time of cystectomy, before any postoperative ERAS component such as early feeding or mobilization could have taken effect, the tumor immune differences are cross-sectional observations rather than evidence that ERAS remodels the tumor microenvironment. They may reflect pre-existing tumor biology, differences in surgical approach, calendar-period effects, or other confounders. Indeed, the ERAS group had shorter operative times, less blood loss, lower transfusion rates, and more frequent minimally invasive surgery, all of which could independently influence both systemic immunity and tumor immune features.

Clinically, the ERAS group fared better on nearly every recovery measure. Time to first flatus was 2.1 days versus 3.4 days, first oral intake occurred at 8.2 hours versus 28.7 hours, and first mobilization at 12.4 hours versus 24.6 hours. Postoperative length of stay averaged 4.8 days compared with 7.2 days, resting pain scores on the first day after surgery were 3.2 versus 5.1 on a ten-point scale, and total hospitalization costs were 22.4 percent lower. The overall rate of 30-day infectious complications was numerically lower in the ERAS group at 19.0 percent versus 33.3 percent, but this difference did not reach conventional statistical significance after recalculation, with a P value of 0.068.

Survival analyses, while exploratory, added another layer. Among patients with available follow-up, descriptive three-year overall survival proportions were 78.1 percent in the ERAS cohort and 68.3 percent in the conventional cohort, though the authors stress these are not formal Kaplan-Meier estimates for the full cohort. In multivariable Cox models, ERAS management was associated with an overall survival hazard ratio of 0.58, and an eight-gene immune signature comprising cytotoxic effectors, exhaustion markers, FOXP3, CD163, and IL6 showed an even stronger association at a hazard ratio of 0.47. Notably, the survival benefit associated with ERAS appeared concentrated in patients whose tumors had high tumor mutational burden, with a hazard ratio of 0.41 in that subgroup and a nominal interaction P value of 0.048.

The authors are unequivocal that these biomarker and survival findings are hypothesis-generating rather than validated. The four-marker index and eight-gene signature were developed and tested in the same retrospective cohort, creating a real risk of overfitting, and only 33 infectious events were available for the predictive analysis. The single-center historical-control design means ERAS exposure is tightly correlated with calendar period, and secular improvements in surgical technique, infection control, and systemic therapy could account for some of the observed differences. Mean follow-up was approximately 24 months, limiting interpretation of three-year outcomes. What the study does establish is a detailed immunological portrait of what happens to the immune system after major cancer surgery under two different care philosophies, and a roadmap for the prospective, contemporaneous trials with longitudinal immune sampling and paired tumor biopsies that will be needed before any of these signals can guide clinical practice.

Subject of Research: Perioperative immunogenomic differences between ERAS-based and conventional nursing care in muscle-invasive bladder cancer patients undergoing radical cystectomy

Article Title: Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer

Article References: Xin, L.-L., Guo, J.-J., Zheng, X.-Y., & Li, Z.-Y. (2026). Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer. Frontiers in Genetics, 17, Article 1967034. https://doi.org/10.3389/fgene.2026.1967034

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1967034

Keywords: bladder cancer, ERAS, radical cystectomy, perioperative immunogenomics, CD8 T cells, tumor immune microenvironment, immune biomarkers, interleukin-6, tumor mutational burden, spatial transcriptomics, nursing care, infectious complications

The patient first noticed abnormal bleeding on March 7, 2026, and hysteroscopy at a local hospital quickly confirmed endometrioid adenocarcinoma. Imaging at Qilu Hospital showed an irregular endometrial mass of roughly 4.6 by 3.7 by 2.5 centimeters with internal branching vessels, and pelvic magnetic resonance imaging revealed a slightly larger lesion with the restricted diffusion typical of malignancy. Her only laboratory abnormality was a mildly elevated CA125 of 49.7 U/mL. She had no family history of gynecologic or hereditary cancers, and after undergoing a total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy, pathology showed a FIGO grade 2 endometrioid carcinoma invading about 20 percent of the myometrium, with focal lymphovascular invasion but no lymph node involvement and a final stage of pT1aN0, corresponding to FIGO 2009 stage IA.

What transformed this from an ordinary early-stage cancer case into a scientific puzzle was next-generation sequencing. Using a 572-gene hybrid-capture panel on tumor tissue containing roughly 45 percent tumor cells, the team identified a rare variant in the exonuclease domain of POLE, the gene encoding DNA polymerase epsilon: c.833C>A, resulting in a threonine-to-lysine substitution at position 278, or p.T278K. This variant sat at a variant allele frequency of 40.42 percent, and manual review of the raw sequencing data confirmed 440 reads at the locus with 187 supporting the alternate T allele. Alongside it, sequencing uncovered two separate frameshift variants in MSH6, a key mismatch repair gene, both hitting the same nucleotide position c.3261 within a low-complexity sequence but predicting differently truncated proteins.

The genomic consequences were dramatic. The tumor’s mutational burden reached 370.0 mutations per megabase, firmly in the ultramutated range reserved for POLE-driven cancers, and microsatellite analysis showed profound instability with an MSI score of 1279.88, far above the positivity threshold of 200. The substitution profile reinforced the POLE story: 26.35 percent of coding variants were C>A transversions and 8.87 percent were T>G substitutions, the classic nucleotide fingerprint left by a failed DNA proofreading enzyme. Additional driver mutations in PTEN, PIK3CA, ARID1A, PPP2R1A, and FGFR2, plus alterations in DNA damage response genes including BRCA2, ATM, ATR, and RAD54L, rounded out a genomic landscape typical of endometrial carcinoma, and a TP53 missense variant was detected by sequencing even though p53 immunostaining looked wild-type.

Immunohistochemistry added a second layer of complexity. The tumor showed subclonal loss of the mismatch repair proteins MLH1, PMS2, and MSH6, with retained MSH2 expression, and methylation-specific PCR detected MLH1 promoter methylation. Taken together, these findings meant the tumor carried features of not one but two of the four molecular classifiers established by The Cancer Genome Atlas: the POLE-ultramutated group, known for excellent prognosis, and the microsatellite instability-hypermutated group driven by mismatch repair deficiency. Such multiple-classifier endometrial carcinomas are uncommon, and interpreting a rare POLE variant within one of them is where the diagnostic challenge truly begins.

Most pathogenic POLE mutations cluster at well-known hotspot residues such as p.P286R, p.V411L, p.S297F, p.A456P, and p.S459F. The p.T278K variant is different. It lies within the Exo I motif of the exonuclease domain, immediately adjacent to the catalytic residue E277 and inside the DNA-binding cleft, a location that raises suspicion but does not by itself prove pathogenicity. To address exactly this problem, León-Castillo and colleagues developed an evidence-based scoring framework that integrates tumor mutational burden, the proportion of C>A and T>G substitutions, insertion-deletion frequency, and recurrence data to separate genuine proofreading-deficient variants from variants of uncertain significance.

Applying that framework to this tumor, the researchers assigned one point each for the ultrahigh tumor mutational burden, the C>A proportion, the T>G proportion, and the C>G proportion, but no points for the indel proportion of 9.17 percent or for recurrence, since p.T278K was absent from the TCGA endometrial carcinoma cohort and represented by only a single record in COSMIC. The resulting exploratory POLE score of 4, combined with the characteristic substitution spectrum, aligns the tumor squarely with the POLE-ultramutated profile, though the authors caution that the framework was built on whole-exome data and its use with targeted panels should be regarded as supportive rather than definitive. Prior evidence strengthens the case: before this report, p.T278K had been documented in only two patients with endometrial carcinoma, one of whom showed the same ultramutated phenotype and a POLE score of 4, and a yeast-based reversion assay has demonstrated a mutator phenotype for this variant, providing functional evidence of impaired proofreading.

The dual MSH6 frameshift variants tell their own fascinating story. Because they arise as reciprocal insertion and deletion events at the same nucleotide within a repetitive, low-complexity sequence, and because their variant allele frequencies differ unequally at 17.64 and 34.94 percent, they are most consistent with secondary somatic events arising through replication slippage in an already hypermutable genome, a phenomenon previously described in tumors that lose both polymerase proofreading and mismatch repair. Yet both variants are classified in ClinVar as pathogenic in the germline context, and because sequencing was performed on tumor tissue without matched normal DNA, a germline origin could not be excluded. The team therefore recommended peripheral-blood germline testing, a step with major implications for the patient’s relatives. Similarly, MLH1 promoter methylation plausibly explains the subclonal MLH1 and PMS2 loss, making this apparently only the third reported endometrial carcinoma with co-occurring POLE alteration and MLH1 promoter methylation, although the bulk-tumor assay used cannot establish spatial correspondence between the methylation and the patchy protein loss.

Why does all this molecular detective work matter clinically? Because molecular classification now directly determines treatment intensity. Under the 2023 FIGO molecular staging system, a pathogenic POLE mutation in a tumor like this one places it in stage IAmPOLEmut, a category with such an excellent prognosis that adjuvant therapy can often be safely omitted. Even setting the POLE question aside, the tumor’s grade 2 endometrioid histology, limited myometrial invasion, focal lymphovascular invasion, negative sentinel nodes, and mismatch repair deficiency would satisfy FIGO 2023 IA2 criteria and place the patient in the low-risk category. Accordingly, the patient received no adjuvant therapy, a decision consistent with the 2025 ESGO-ESTRO-ESP guidelines, and at four months of follow-up her CA125 had normalized, pelvic ultrasound showed no disease, and there was no evidence of recurrence. Her mismatch repair-deficient status nonetheless remains clinically valuable: should the cancer ever return or progress, MSI-H tumors are prime candidates for immune checkpoint inhibitors.

The case does carry limitations. Tumor-only sequencing cannot definitively distinguish somatic from germline variants, targeted-panel analysis rather than whole-exome sequencing constrains mutational signature analysis, the MLH1 methylation test was qualitative on bulk tissue, and follow-up remains short. The discordance between the TP53 sequencing result and the wild-type p53 staining pattern also remains unexplained, possibly reflecting intratumoral heterogeneity or differences in protein regulation, though it did not alter classification or management. Still, by converging from three independent directions, genomic phenotype, prior clinical observations, and functional assay data, the report substantially strengthens the argument that p.T278K is a genuine proofreading-deficient variant rather than a passenger, and it offers a practical template for pathologists confronting rare POLE variants in tumors that carry multiple molecular fingerprints. For the growing number of patients whose cancers are now classified at the DNA level, that template may help ensure the right patients receive less treatment, and the right ones receive more.

Subject of Research: Molecular classification of endometrial carcinoma harboring a rare POLE p.T278K variant and MSH6 frameshift mutations

Article Title: Case Report: Endometrial carcinoma harboring a rare POLE p.T278K variant and dual MSH6 frameshift variants

Article References: Yang, Y., Luo, H., Yan, H., Yu, H., Ma, X., Teng, Q., Zhang, L., Ye, J., Yuan, Z., & Zhang, Q. (2026). Case Report: Endometrial carcinoma harboring a rare POLE p.T278K variant and dual MSH6 frameshift variants. Frontiers in Oncology, 16, Article 1964637. https://doi.org/10.3389/fonc.2026.1964637

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1964637

Keywords: endometrial carcinoma, POLE, p.T278K, MSH6, mismatch repair deficiency, microsatellite instability, tumor mutational burden, MLH1 promoter methylation, molecular classification, León-Castillo scoring, next-generation sequencing, gynecologic oncology

DIMT1 belongs to a family of enzymes that chemically decorate ribosomal RNA, the structural and catalytic backbone of the ribosome. By transferring methyl groups to specific adenine bases in the 18S rRNA of the small ribosomal subunit, DIMT1 helps ensure that ribosomes are assembled correctly and function with the fidelity that protein synthesis demands. For years, this activity was viewed as basic housekeeping biology. But a growing body of evidence has linked disturbances in ribosome biogenesis—the intricate process of building ribosomes from scratch—to cancer. Rapidly dividing tumor cells need an enormous supply of ribosomes, and enzymes that drive ribosome production can become unwitting accomplices in malignant growth. Whether DIMT1 fit that pattern was, until now, an open question.

To answer it, the research team mounted a pan-cancer analysis, a strategy that sweeps across many tumor types simultaneously rather than focusing on a single disease. They integrated transcriptomic, genomic, and epigenetic data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project, two of the largest public repositories of human molecular data. Using a battery of bioinformatics approaches, the investigators mapped where and how strongly DIMT1 is expressed, whether its expression levels predict patient survival, how often the gene is altered or chemically silenced through DNA methylation, and how its activity relates to the immune cells that swarm within and around tumors. The scale of the analysis allowed patterns to emerge that would be invisible in any single cancer type.

The first major finding concerned location and abundance. DIMT1, consistent with its role in the nucleolus where ribosomes are assembled, showed a predominantly nuclear localization, and its expression was aberrant—either elevated or depressed—across multiple cancer types when compared with healthy tissues. More strikingly, in several malignancies, high DIMT1 expression tracked with unfavorable survival outcomes. Patients whose tumors expressed more of the enzyme tended to fare worse, a correlation that positions DIMT1 as a potential prognostic biomarker: a measurable signal that could, in principle, help clinicians gauge how aggressive a tumor is likely to be and how intensively it should be treated.

Beyond expression and survival, the pan-cancer survey revealed distinct patterns of genomic and epigenetic alteration at the DIMT1 locus. The gene’s regulatory landscape, shaped by DNA methylation—the addition of chemical tags that can dampen gene activity—varied from one cancer type to another, hinting that different tumors may hijack DIMT1 through different mechanisms. The team also uncovered significant associations between DIMT1 expression and the tumor immune microenvironment, the complex ecosystem of immune cells that infiltrates cancers and can either attack them or be co-opted to protect them. DIMT1 levels correlated with immune infiltration profiles and with the activity of immune regulatory genes, the molecular switches that determine whether a tumor is visible to the immune system or cloaked from it.

Perhaps most intriguingly for the era of immunotherapy, the analysis tied DIMT1 expression to cancer-type-specific characteristics of tumor mutational burden (TMB) and microsatellite instability (MSI). These two genomic signatures are among the best-established predictors of response to immune checkpoint inhibitors, the blockbuster drugs that unleash T cells against tumors. A link between a ribosome biogenesis factor and these immune-relevant metrics suggests that DIMT1 may sit at a crossroads where the cell’s protein-making machinery meets its immune visibility—an intersection that cancer biologists are only beginning to map. If confirmed in functional studies, the connection could help explain why some tumors respond brilliantly to immunotherapy while others remain stubbornly resistant.

Because the pan-cancer data pointed most compellingly toward gastric cancer, the team narrowed their focus there. Gastric cancer remains a leading cause of cancer death worldwide, and new molecular targets are urgently needed. Functional enrichment analysis of genes co-expressed with DIMT1 in gastric tumors revealed that they cluster in pathways governing RNA metabolism, cell-cycle regulation, and immune-related processes—a coherent biological story in which a ribosome assembly factor is entangled with the very programs that drive uncontrolled proliferation and immune evasion. Drug sensitivity analysis added a translational dimension, probing how DIMT1 expression relates to the responsiveness of cancer cell lines to a panel of candidate compounds.

The critical step, however, was experimental validation. Correlation, as every scientist knows, is not causation. So the researchers turned off DIMT1 in gastric cancer cells and watched what happened. In vitro, silencing the gene significantly inhibited the proliferation, migration, and invasion of gastric cancer cells—the three capabilities that allow a tumor to grow, spread, and colonize distant organs. The team then extended the work into living systems, conducting in vivo experiments in gastric cancer models that were approved by an animal ethics committee and conducted under institutional guidelines. In these animal models, depleting DIMT1 suppressed tumor growth, providing direct evidence that the enzyme is not merely a passive passenger alongside cancer but an active promoter of malignant behavior.

Taken together, the study delivers a two-part message. First, DIMT1 is a bona fide pan-cancer biomarker candidate, with expression patterns, genomic alterations, methylation signatures, and immune associations that can be systematically cataloged across tumor types and potentially harnessed for prognosis. Second, in gastric cancer at least, DIMT1 is functionally important: removing it cripples the malignant phenotype in the laboratory and in animal models. That dual identity—biomarker and dependency—makes DIMT1 a candidate target for future therapeutic investigation. Drugs that inhibit DIMT1, or strategies that exploit its expression to stratify patients for immunotherapy, are conceivable next steps, though the path from a validated target to a clinically approved medicine is long and uncertain.

The work also exemplifies a broader shift in cancer research. Pan-cancer analyses powered by public data repositories such as TCGA, GTEx, and the many databases the authors acknowledge—from TIMER2.0 and LinkedOmics to the Human Protein Atlas and the Genomics of Drug Sensitivity in Cancer—allow researchers to turn raw molecular data into testable hypotheses at unprecedented speed. When such computational surveys are paired with rigorous bench and animal experiments, as they were here, the result is a research pipeline that can elevate an obscure housekeeping enzyme into a credible therapeutic lead. For DIMT1, the journey from ribosome assembly line to cancer clinic has only just begun, but the map drawn by Liu, Yang, and Luo gives the field a clear route to follow.

Subject of Research: Pan-cancer analysis of the rRNA methyltransferase DIMT1 as a prognostic and immune-associated biomarker with experimental validation in gastric cancer

Article Title: Comprehensive pan-cancer analysis of DIMT1 reveals its prognostic significance and immune-associated characteristics with experimental validation in gastric cancer

Article References: Liu, S., Yang, J., & Luo, M. (2026). Comprehensive pan-cancer analysis of DIMT1 reveals its prognostic significance and immune-associated characteristics with experimental validation in gastric cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-16956-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16956-6

Keywords: DIMT1, pan-cancer analysis, gastric cancer, ribosome biogenesis, tumor immune microenvironment, prognosis, biomarker, tumor mutational burden, microsatellite instability, DNA methylation, immunotherapy, BMC Cancer

The research team, led by Chao Yu and Siyu Liu with corresponding authors Yakun Wang and Xiaotian Zhang, assembled a cohort of 563 patients with stage III or IV gastric cancer or gastroesophageal junction adenocarcinoma, all of whom had paired tumor and normal tissue analyzed by targeted sequencing. The investigators call this the QZ563 cohort. Within it, a subset of 391 patients carried detailed clinicopathologic, biomarker, treatment, and survival information, forming the Clinical391 cohort used for deeper outcome analyses. By layering somatic mutations, tumor mutational burden, microsatellite instability status, metastatic patterns, and treatment-related biomarkers onto this clinical foundation, the team built a multidimensional map of advanced gastric cancer as it actually presents in Chinese hospitals.

The mutational landscape that emerged was dominated by familiar names. TP53 was altered in 70.8 percent of tumors, cementing its role as the single most frequently disrupted gene in advanced gastric cancer. Alongside it, ARID1A, CDH1, and PIK3CA ranked among the most commonly mutated genes, a pattern consistent with prior genomic surveys of the disease. But the study’s real contribution lies not in cataloging the usual suspects. Instead, the researchers asked how clinically actionable biomarkers carve up the patient population, and whether the resulting categories carry meaningful biological and prognostic differences that standard staging alone cannot capture.

One of the most clinically consequential findings concerns a small but important subgroup: patients whose tumors lack any of the established treatment-related biomarkers. The team labeled this group treatment-biomarker-negative gastric cancer, and their analysis revealed that these tumors are molecularly heterogeneous rather than uniformly indolent or uniformly aggressive. In other words, patients who test negative for actionable markers are not a single biological entity; they represent a mixed collection of genomic states that current biomarker panels do not resolve. The authors are careful to note that this subgroup warrants further validation, but the implication is provocative. A negative biomarker result may conceal as much biological diversity as a positive one, and refining how these patients are characterized could eventually open new therapeutic doors.

Metastatic phenotype added another layer of clinically relevant heterogeneity. By comparing tumors from patients with peritoneal involvement against those with liver metastases, the researchers identified distinct patterns of pathway-level mutation preference, suggesting that the route a gastric cancer takes when it spreads is written, at least in part, into its genome. This distinction matters because peritoneal and liver metastases carry different prognoses and respond differently to systemic therapy. A genomic framework that recognizes metastatic phenotype as a biologically meaningful axis, rather than a mere anatomical detail, could help clinicians anticipate disease trajectories and select treatments more rationally for stage IV patients.

The study’s most striking molecular discovery, however, centers on two chromatin-regulating genes: KMT2C and KMT2D. Loss-of-function alterations in these genes, which disrupt histone methyltransferase complexes that help orchestrate gene expression, were present in 6.4 percent of the QZ563 cohort. That modest frequency conceals a dramatic association. Among tumors carrying KMT2C or KMT2D loss-of-function changes, 48.3 percent were microsatellite instability-high, compared with just 2.7 percent of tumors lacking these alterations, a difference the authors report as highly statistically significant. In plain terms, when the epigenetic machinery governed by KMT2C and KMT2D breaks down, the genome’s mismatch repair system appears far more likely to falter as well, unleashing the mutational storm that defines MSI-high disease.

Crucially, the association did not stop at microsatellite status. Within both microsatellite-stable and MSI-high strata, KMT2C/D loss-of-function tumors showed higher tumor mutational burden than their wild-type counterparts, indicating that these chromatin alterations push genomic instability upward even within established MSI categories. The researchers then cross-checked this pattern against The Cancer Genome Atlas stomach adenocarcinoma dataset, known as TCGA-STAD, and found the same molecular signature, lending independent support to the finding. Yet a cautionary note accompanies the excitement: KMT2C/D loss-of-function status was not associated with a survival benefit in this cohort. High mutational burden is often assumed to predict better responses to immunotherapy, but the data here suggest that KMT2C/D-linked hypermutation alone does not translate into improved outcomes, at least within this retrospective framework.

To move from association toward therapeutic hypothesis, the team turned to DepMap, a large-scale cancer dependency resource that catalogs which genes cancer cell lines cannot survive without. Their analyses nominated WRN, a DNA helicase gene, as a candidate dependency in KMT2C/D loss-of-function MSI models. WRN dependency in MSI-high cancers has emerged in recent years as one of the most tantalizing synthetic lethal opportunities in oncology, and this study extends that concept into the KMT2C/D-altered subset. The authors are explicit that this remains hypothesis-generating and requires functional validation before any clinical translation, but the nomination of a druggable vulnerability within a molecularly defined subgroup exemplifies how large clinical-genomic datasets can seed the next generation of precision trials.

The study also integrated transcriptomic data from TCGA-STAD to probe what KMT2C/D loss-of-function means biologically within the MSI background, examining immune-related and non-immune signature scores between altered and wild-type tumors. Sensitivity analyses confirmed the directional concordance of co-mutation patterns between the Chinese cohort and TCGA, and the researchers stratified their TMB comparisons by MSI status to ensure the association was not simply an artifact of hypermutation. Methodologically, the work illustrates the value of pairing a well-annotated single-institution cohort with public genomic resources: the clinical depth of the Chinese data anchors the findings in real-world patient care, while the external datasets guard against cohort-specific artifacts.

For patients and clinicians, the takeaway is twofold. First, biomarker testing in advanced gastric cancer is not merely a pass-fail gate; the clinical and genomic context surrounding a biomarker result, including metastatic pattern and chromatin gene status, carries information that current decision trees largely ignore. Second, the KMT2C/D-MSI axis offers a potential new lens for subdividing the immunotherapy-sensitive population, one that could eventually explain why some hypermutated tumors respond spectacularly to checkpoint inhibitors while others do not. The study, approved by the Ethics Committee of Peking University Cancer Hospital and funded by Chinese national and municipal science programs, is retrospective by design, and the authors themselves frame the WRN finding as requiring experimental confirmation. Even so, in a disease where one in five patients may harbor molecular features invisible to standard panels, this 563-patient genomic atlas marks a meaningful step toward treatment maps that reflect the full genetic complexity of gastric cancer.

Subject of Research: Clinical-genomic stratification of treatment biomarkers and KMT2C/D-associated microsatellite instability heterogeneity in advanced Chinese gastric cancer

Article Title: Clinical-genomic stratification of treatment biomarkers and KMT2C/D-linked MSI heterogeneity in Chinese gastric cancer: a retrospective cohort study

Article References: Yu, C., Liu, S., Zhou, Z., Qin, N., Yang, L., Wang, J., Ding, M., Chong, X., Wang, Y., & Zhang, X. (2026). Clinical-genomic stratification of treatment biomarkers and KMT2C/D-linked MSI heterogeneity in Chinese gastric cancer: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17051-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17051-6

Keywords: gastric cancer, KMT2C, KMT2D, microsatellite instability, tumor mutational burden, WRN dependency, treatment biomarkers, tumor heterogeneity, precision oncology, targeted therapy, immunotherapy biomarkers, retrospective cohort study

The research team carried out whole-exome sequencing on tumor samples and matched blood controls from 37 patients with hepatocellular carcinoma who underwent liver transplantation at their center between January 2019 and July 2021, all selected according to the Hangzhou criteria, an expansion of the classic Milan criteria that allows somewhat larger or more numerous tumors to qualify for transplant. Sequencing was performed on the Illumina NovaSeq6000 platform at an average depth of 500-fold for tumor tissue and 100-fold for blood, a level of coverage deep enough to detect low-frequency somatic mutations with confidence. The team then asked a deceptively simple question: do the mutations carried by tumors that came back within a year differ systematically from those that did not?

The clinical picture was sobering. Twelve of the 37 patients, or 32.4 percent, experienced recurrence within one year of transplantation, a figure broadly consistent with previous reports regardless of whether Milan or Hangzhou criteria were used. Patients whose disease recurred early had dramatically worse overall survival than those who did not, with the difference reaching high statistical significance. Strikingly, however, when the researchers compared the two groups on standard clinical variables, age, preoperative alpha-fetoprotein levels, tumor size, tumor number, differentiation grade, and prior treatment before transplant, none of the differences reached statistical significance. Microvascular invasion, the presence of tumor cells within blood vessels, was more than twice as common in the recurrence group, but even this well-known risk factor fell just short of significance in the direct comparison.

At the genomic level, the mutational landscape of the cohort mirrored what is known about hepatocellular carcinoma more broadly. The most frequently altered genes were BCLAF1, mutated in 73 percent of patients, followed by MUC4 at 57 percent, TP53 at 49 percent, FMN2 at 49 percent, and TTC7A at 46 percent. These genes are not random bystanders: BCLAF1 has been shown to promote tumor angiogenesis by regulating the transcription factor HIF-1α, MUC4 mutations have been linked to poorer responses to immunotherapy combined with targeted therapy, and TP53 is the most commonly mutated gene in liver cancer, shaping both progression and prognosis. The most common mutation types were missense mutations, which alter a single amino acid, followed by splice-site and nonsense mutations, which can disrupt or truncate the encoded protein.

When the researchers compared mutation frequencies between the recurrence and non-recurrence groups across 9,658 tested genes, they identified 32 genes with nominal differences, 25 of which were detected only in the recurrence group. TP53 and the giant structural gene TTN showed the highest mutation frequencies among these differential genes. It is important to note that after applying the Benjamini–Hochberg correction for multiple testing across the full gene panel, none of these frequency differences retained formal statistical significance, a caveat the authors acknowledge transparently. Tumor mutational burden and tumor neoantigen burden, two measures often associated with immunotherapy response, also did not differ significantly between the groups, and neither was associated with recurrence-free or overall survival in this cohort.

The picture changed when the team turned to survival analysis. Univariate Cox regression identified 304 genes whose mutations were significantly associated with poorer recurrence-free survival, and after adjusting for age, alpha-fetoprotein, tumor mutational burden group, and microvascular invasion in multivariate models, 205 of these remained. For overall survival, 811 genes were significant in univariate analysis and 482 survived multivariate adjustment. Among the clinical variables, elevated alpha-fetoprotein and microvascular invasion were each associated with poorer recurrence-free survival in univariate analysis, and microvascular invasion with poorer overall survival, but no clinical factor proved to be an independent predictor once the models were fully adjusted. The genomic data, in other words, carried prognostic information that the standard clinical variables could not.

From this analysis the researchers distilled a 13-gene signature comprising BOD1L1, C14orf159, CSPG4, EML6, KCNB2, OR4D10, PACS2, SPRED3, TAF1, VRK3, FOXO3, NDUFS7 and TTN. These genes were selected by intersecting those with high mutation frequencies in the recurrence group with the independent prognostic factors identified in the multivariate models. Ten of the thirteen genes carried variants found exclusively in patients who recurred within one year. When patients were classified as high-risk if they carried a mutation in any of the 13 genes and low-risk if all 13 were wild-type, the high-risk group showed significantly worse recurrence-free survival and overall survival, with the model retaining independent significance in multivariate Cox regression for both endpoints.

The model’s performance metrics were encouraging for a study of this size. A receiver operating characteristic analysis of recurrence at any time during follow-up yielded an area under the curve of 0.73, while leave-one-out cross-validation, a demanding internal validation approach in which each patient is successively held out and predicted by the remaining data, produced a mean AUC of 0.864. The team also validated the signature against the TCGA-LIHC dataset, an independent public cohort of liver cancer genomes, where nine of the key genes showed supporting evidence. Machine learning approaches, including LASSO regression with ten-fold cross-validation, random forest, and XGBoost, were used to construct and assess the model, and the proportional hazards assumption was verified using Schoenfeld residual tests.

Several of the signature genes have plausible biological connections to cancer behavior. TAF1 has been proposed as a driver gene in hepatocellular carcinoma development, FOXO3, a transcription factor governing stress responses and autophagy, has been linked in a meta-analysis of more than 1,000 cases to tumor development and shorter survival, and TTN mutations have been associated with altered immune infiltration and poor prognosis in liver cancer. Genes such as KCNB2, a potassium channel, and CSPG4, a cell-surface proteoglycan that has attracted interest as an immunotherapy target, hint at mechanisms ranging from ion signaling to tumor-stroma interaction that may shape post-transplant recurrence, though the authors stress that functional studies are still needed to establish causality.

The study’s limitations are clear and the authors state them candidly. With only 37 patients, and just 12 in the recurrence subgroup, the statistical power is limited and the risk of false negatives is real; the single-center, retrospective design introduces potential selection bias, and no functional experiments were performed to demonstrate how these mutations drive recurrence. The survival analyses also rely on nominal P values rather than genome-wide correction, and the mutation-frequency differences did not survive multiple-testing adjustment. Even so, the work represents one of the first systematic attempts to connect exonic tumor variants with post-transplant recurrence in hepatocellular carcinoma, and it delivers a concrete, testable hypothesis: a 13-gene panel that could, if validated in larger prospective cohorts, help clinicians identify high-risk patients before surgery and tailor surveillance, adjuvant therapy, and transplant selection accordingly. For a disease in which recurrence after transplantation remains so difficult to predict and so devastating when it occurs, that would be a meaningful step forward.

Subject of Research: Genomic predictors of hepatocellular carcinoma recurrence after liver transplantation

Article Title: Genomic alterations in hepatocellular carcinoma patients undergoing liver transplantation predict recurrence and prognosis

Article References: Li, X., Cai, H., Wang, C., Qi, Y., Yu, T., Zhang, Q., Liu, H., Luo, N., Chen, J., Cheng, S., Cai, J., & Wu, B. (2026). Genomic alterations in hepatocellular carcinoma patients undergoing liver transplantation predict recurrence and prognosis. Heliyon, 12(15), Article e45555. https://doi.org/10.1016/j.heliyon.2026.e45555

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45555

Keywords: hepatocellular carcinoma, liver transplantation, whole-exome sequencing, cancer recurrence, gene signature, TP53, TTN, tumor mutational burden, microvascular invasion, prognosis, genomics, oncology

Mitochondria are far more than passive energy suppliers. In cancer cells, they participate in metabolic reprogramming, redox balance, cell death decisions, and signaling to the surrounding tumor microenvironment. To keep these organelles functional, cells run a quality control program that includes mitochondrial fission and fusion, mitophagy, the removal of damaged proteins, and the maintenance of mitochondrial DNA integrity. Disruptions in this program have been implicated in tumor progression and treatment resistance, but the question the Chinese team set out to answer was whether the transcriptional activity of mitochondrial quality regulation genes carries meaningful prognostic information in breast cancer, and whether it connects to the immune and stromal features of tumors.

To build their gene panel, the authors curated twenty mitochondrial quality regulation genes from MitoCarta 3.0, a comprehensive inventory of mitochondrial proteins, together with genes identified in the published literature. They then integrated two large public datasets, The Cancer Genome Atlas breast cancer cohort and the GSE20685 dataset, yielding 1,422 samples for molecular subtyping and 1,421 with survival information. Using consensus clustering, a method that groups samples based on the stability of their expression patterns across repeated clustering runs, the team identified two transcriptional states defined by the activity of these mitochondrial genes. The distinction was not merely descriptive. Patients in Cluster A had significantly better overall survival than those in Cluster B, with a P value of 0.006, indicating that the mitochondrial quality control signature captured clinically relevant tumor biology.

Having established that these transcriptional states matter, the researchers moved from subtypes to a quantitative tool. They applied Cox regression and LASSO-Cox analysis, a technique that shrinks regression coefficients to prevent overfitting and select the most informative predictors, to distill the signal into a seven-gene prognostic score. The score stratified survival in the training subset, the internal testing subset, and the pooled cohort, with all comparisons reaching P values below 0.001. Importantly, the team did not stop at unadjusted associations. After accounting for available clinicopathological factors, the standardized score remained significantly associated with overall survival in the source-stratified pooled analysis, with a hazard ratio of 1.775 per standard deviation increase and a 95 percent confidence interval of 1.554 to 2.027. In other words, each standard deviation rise in the score corresponded to roughly a 78 percent increase in the hazard of death.

A recurring weakness of prognostic signatures in oncology is their failure to replicate outside the data in which they were built. To address this, the authors harmonized expression scales across platforms in an outcome-blind manner and tested the score in GSE199633, an independent cohort of 637 breast cancer patients. The score retained its prognostic association in this external validation, with a hazard ratio of 1.378 and a 95 percent confidence interval of 1.109 to 1.712, and a P value of 0.004. The authors are candid about the limits of this result: adding the score to existing models improved model fit, but the incremental gain in discrimination, the ability to correctly rank patients by risk, was modest. This transparency is notable in a field where headline claims often outpace the statistical fine print.

Beyond survival prediction, the study connects mitochondrial quality regulation to the tumor microenvironment, the ecosystem of immune cells, fibroblasts, blood vessels, and signaling molecules that surrounds cancer cells. Using three complementary computational approaches, single-sample gene set enrichment analysis, CIBERSORT for estimating immune cell composition from bulk RNA data, and ESTIMATE for scoring stromal and immune content, the team found that high-risk tumors displayed distinct immune and stromal features derived from bulk expression profiles. High-risk tumors also carried a higher tumor mutational burden, a measure of the number of mutations per megabase of DNA that has become an important biomarker in immunotherapy research. The convergence of mitochondrial transcriptional states, immune infiltration patterns, and mutational load suggests that mitochondrial quality control may help shape the evolutionary and immunological context in which tumors grow.

The most striking tissue-level finding concerns CXCL9, a chemokine known for recruiting T cells to sites of inflammation and tumors. Using reverse transcription quantitative PCR and Western blotting, the researchers confirmed that CXCL9 protein abundance was higher in paired tumor tissue than in adjacent non-tumor tissue, with a P value below 0.001. They then turned to multiplex immunohistochemistry, a technique that stains multiple protein markers simultaneously on a single tissue section, applied to a 120-case tissue microarray. The spatial analysis revealed a positive correlation between CXCL9 signal and the density of iNOS-positive M1-like macrophages, the classically activated, antitumor-polarized members of the macrophage family, with a correlation coefficient of 0.3203 and a P value below 0.001. This links the bulk-expression signature to an actual cellular population visible under the microscope, a step that many computational prognostic studies never take.

The study’s design reflects the current best practice in bioinformatic oncology research: multi-cohort integration, adjustment for confounders, external validation, and experimental confirmation of selected computational findings. The tissue microarray work was approved by the Ethics Committee on Biological Science and Technology of Hunan Aifang Biological Co., Ltd., and conducted under the Declaration of Helsinki with written informed consent. The research was funded by the Interdisciplinary Research Program in Medicine and Engineering and the Clinical Medical Research 4310 Program of the University of South China. The corresponding author is Yuehua Li, and the first three authors, Huaiwen Pu, Tingjing Li and Renji Liang, contributed equally to the work.

What makes this study worth watching is its framing of mitochondria as a bridge between tumor-intrinsic biology and the immune landscape. If mitochondrial quality regulation genes help determine whether a breast tumor recruits antitumor macrophages or evolves a high mutational burden, they could eventually inform decisions about immunotherapy, patient risk stratification, and the design of trials targeting metabolic pathways. The authors themselves are careful to position the seven-gene score as a framework that warrants further independent clinical validation and mechanistic investigation rather than a ready-made clinical test. The modest incremental discrimination in the external cohort is a reminder that even well-validated signatures must earn their place alongside established clinicopathological variables. Still, the convergence of survival associations, microenvironment characterization, and spatial protein-level evidence gives this mitochondrial angle a credibility that many gene-signature papers lack, and it opens a concrete research agenda for laboratories interested in how the quality control of cellular power plants shapes the fate of breast tumors and the patients who carry them.

Subject of Research: Mitochondrial quality regulation gene expression, prognostic modeling, and tumor microenvironment characterization in breast cancer

Article Title: MQRG-associated transcriptional heterogeneity and a seven-gene prognostic signature in breast cancer: multi-cohort evaluation and tumor microenvironment characterization

Article References: Pu, H., Li, T., Liang, R., Fan, Z., Tang, B., Luo, Y., Yi, X., Xie, L., & Li, Y. (2026). MQRG-associated transcriptional heterogeneity and a seven-gene prognostic signature in breast cancer: multi-cohort evaluation and tumor microenvironment characterization. BMC Cancer. https://doi.org/10.1186/s12885-026-16950-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16950-y

Keywords: breast cancer, mitochondrial quality control, prognostic signature, tumor microenvironment, CXCL9, transcriptomics, bioinformatics, TCGA, macrophages, tumor mutational burden, gene expression profiling, multiplex immunohistochemistry

The technical core of the original study rests on a multi-omics comparison of tumors from people living with HIV and comparable tumors from HIV-negative patients. The researchers integrated whole-exome sequencing, which catalogs the full repertoire of coding mutations in a tumor, with RNA sequencing, which reveals which of those mutated genes are actually transcribed, and paired both with detailed immune profiling of the tumor microenvironment. If HIV had acted as a viral hypermutator, driving oncogenesis by flooding the genome with mutations, the tumors from people living with HIV should have shown elevated tumor mutational burden and a distorted antigenic landscape. They did not. Mutational burden and antigen presentation machinery appeared broadly intact, yet the immune response to those antigens was profoundly blunted.

This dissociation is what makes the finding paradigm-shifting, as Yang and colleagues emphasize in their letter. Historically, excess cancer risk in people living with HIV has been attributed to generalized immunosuppression or to co-infections with viruses such as human papillomavirus or Epstein-Barr virus. The new data pivot the explanatory model toward a HIV-mediated bystander effect on antitumor immunity: the virus does not create the cancer’s mutations, but it disables the surveillance system that would otherwise detect and eliminate cells bearing them. In immunological terms, the target list remains written, but the readers assigned to act on it have been depleted, exhausted, or functionally silenced.

The immune profiling in the study described a recognizable signature of chronic dysfunction. T cells from patients carried elevated levels of the inhibitory receptors PD-1 and TIM-3, hallmarks of the exhausted state that develops when lymphocytes are chronically stimulated and progressively lose effector function. Alongside this T-cell exhaustion, the natural killer cell repertoire appeared depleted, weakening the innate arm of antitumor surveillance that normally complements cytotoxic T lymphocytes. Together, these defects mean that even when a tumor presents perfectly recognizable neoantigens on its surface, the cellular machinery required to mount a response against them is compromised at multiple levels.

The clinical implications are immediate and consequential for the roughly 38 million people living with HIV worldwide. Immune checkpoint inhibitors, the antibodies that block PD-1, PD-L1, or CTLA-4, have transformed outcomes in NSCLC for the general population, and the exhaustion phenotype documented in this study provides a strong rationale for using them in people living with HIV, particularly as next-generation agents targeting TIM-3 and LAG-3 advance through clinical development. Blocking inhibitory pathways is precisely the intervention that an exhausted T-cell state would seem to call for, and early clinical experience with checkpoint inhibitors in people living with HIV has generally shown acceptable safety.

Yet the letter’s authors argue that checkpoint blockade alone may not be enough. If the fundamental defect lies in the initial recognition and priming of neoantigen-specific responses, then releasing the brakes on T cells that were never adequately activated in the first place may produce only partial reinvigoration. This could explain the heterogeneous clinical responses to checkpoint inhibitors observed among people living with HIV who develop cancer, a variability that likely stems from deeper HIV-related immune dysfunction than the exhaustion markers alone suggest. In a significant subset of patients, the problem may not be an overactive brake but a missing engine.

That reasoning pushes the therapeutic conversation toward combination strategies that actively induce de novo immune responses rather than merely removing suppression. Personalized cancer vaccines built from validated neoepitopes identified by tumor sequencing could supply the priming signal that the endogenous immune system failed to generate, presenting mutant peptides in an immunogenic format that bypasses the defective antigen-presentation step. Adoptive cell therapies, in which T cells are engineered ex vivo to recognize specific tumor antigens and expanded to large numbers before infusion, offer a parallel route around the recognition deficit, effectively outsourcing the surveillance function that HIV has compromised. Both approaches are already advancing in solid tumors more broadly, and the new findings give them a specific rationale in this population.

The letter also frames a set of pressing open questions that will shape the next phase of research. The first concerns mechanism: is the failure of neoepitope recognition due to the physical loss of specific T-cell clones from the repertoire, a generalized defect in antigen presentation potentially mediated by HIV-associated dysfunction of dendritic cells, or some combination of the two? The authors propose that single-cell T-cell receptor sequencing coupled with epitope mapping, performed on both blood and tumor tissue, could resolve the clonal architecture and specificity of whatever residual response remains, distinguishing a hole in the repertoire from a failure of activation.

A second question concerns the reversibility of the defect under long-term suppressive antiretroviral therapy. Modern antiretroviral regimens can drive viral loads to undetectable levels and allow substantial CD4 T-cell recovery, yet it remains unknown whether antitumor immune surveillance is restored in parallel or whether the neoantigen-recognition deficit persists as a scar of chronic infection. Longitudinal studies that track neoantigen-specific immune responses in patients on antiretroviral therapy, ideally before and after a cancer diagnosis and informed by emerging immune monitoring guidelines for this population, would directly address whether the damage is reversible and at what stage intervention is most effective.

Finally, the generalizability of the mechanism extends well beyond lung cancer. If HIV impairs immunosurveillance of tumor neoepitopes as a general principle, then other solid malignancies that are disproportionately prevalent among people living with HIV, such as anal and cervical carcinomas, may be shaped by the same deficit. Confirming or refuting that broader pattern will determine whether the therapeutic recalibration proposed in the letter represents a niche adjustment for NSCLC or a foundational shift in how cancer immunotherapy is designed for the entire population of people living with HIV. Either way, the work of Abbar and colleagues, as distilled by Yang and colleagues, delineates a novel and specific immune deficit that transcends any single tumor type, and it issues a clear imperative: next-generation immunotherapies for this population must rebuild immune recognition, not merely unleash it.

Subject of Research: HIV-induced impairment of neoantigen immune recognition in non-small cell lung cancer and its implications for immunotherapy

Article Title: HIV-induced neoantigen immunodeficiency: a novel mechanism of immune evasion in non-small cell lung cancer and implications for next-generation immunotherapies

Article References: Yang, D., Yang, L., Yang, J., & Wang, G. (2026). HIV-induced neoantigen immunodeficiency: a novel mechanism of immune evasion in non-small cell lung cancer and implications for next-generation immunotherapies. Journal of Translational Medicine, 24(1), Article 1162. https://doi.org/10.1186/s12967-026-08578-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08578-0

Keywords: HIV, non-small cell lung cancer, neoantigens, immune evasion, immune checkpoint inhibitors, T-cell exhaustion, cancer immunotherapy, tumor mutational burden, antiretroviral therapy, personalized cancer vaccines, adoptive cell therapy, people living with HIV

The patient’s disease was discovered almost by accident. During a routine health examination in April 2022, chest computed tomography revealed an irregular mass in the apical segment of the right upper lobe, measuring approximately 5.9 by 5.0 centimeters at its largest cross-section. The lesion sat dangerously close to the mediastinal pleura and the right brachiocephalic vein, and imaging suggested metastatic involvement of right hilar and mediastinal lymph nodes. A percutaneous biopsy confirmed squamous cell carcinoma, one of the two major subtypes of non-small cell lung cancer, supported by a characteristic immunohistochemical profile including strong staining for P63 and cytokeratin markers with negative TTF-1 and NapsinA. Under the eighth edition of the UICC/AJCC staging system, the tumor was classified as T3N2M0, placing it firmly in stage IIIB territory, a stage at which a large proportion of patients are considered inoperable at diagnosis.

Beginning in July 2022, the patient received three 21-day cycles of albumin-bound paclitaxel and cisplatin alongside 1200 milligrams of sugemalimab, an IgG4 monoclonal antibody that blocks the interaction between programmed death-ligand 1 and its receptors on T cells. The only reported toxicity during this period was grade I nausea, a remarkably mild profile for such an aggressive preoperative regimen. After two cycles, a follow-up CT scan showed the tumor had shrunk to roughly 4.8 by 3.7 centimeters, but more striking was the change in its internal character. The soft tissue density had decreased so substantially that the lesion now appeared as a cavity surrounded by minimal ground-glass opacity. By the formal RECIST 1.1 criteria, this counted only as stable disease, a reminder that conventional imaging metrics can dramatically understate the biological impact of immunotherapy, which works by triggering immune infiltration and tissue remodeling rather than rapid tumor collapse.

Surgery took place on October 10, 2022, in the form of video-assisted thoracic surgery with right upper lobectomy and systematic lymph node dissection. The pathological examination told a story the CT scans had only hinted at. The lung interstitium showed extensive fibrosis, lymphocytic infiltration, aggregates of multinucleated giant cells, and small focal calcifications, the archaeological traces of a tumor that had been dismantled by the immune system. Microscopy revealed no definite residual cancer anywhere in the specimen. The bronchial margins were clear, the visceral pleura was uninvolved, and none of the dissected lymph nodes contained metastatic disease or even treatment-related fibrosis, yielding a pathological stage of ypT0N0. The patient then completed one additional cycle of immunochemotherapy after surgery, followed by a planned year of sugemalimab maintenance monotherapy, a strategy embedded in the team’s prospective perioperative chemoimmunotherapy trial registered as NCT04941417.

The case sits within a rapidly shifting treatment landscape. For decades, surgery followed by adjuvant chemotherapy was the standard approach for resectable stage II to III non-small cell lung cancer, yet adjuvant chemotherapy improved five-year overall survival by only about five percentage points. The introduction of immune checkpoint inhibitors changed that calculus. The CheckMate 816 trial, the first phase 3 study of neoadjuvant chemoimmunotherapy in stage IB to IIIA disease, demonstrated that adding the anti-PD-1 antibody nivolumab to chemotherapy raised the pathological complete response rate from 2.2 percent to 24.0 percent and extended event-free survival from 20.8 to 31.6 months. More recently, the KEYNOTE-671 trial tested perioperative pembrolizumab in stage IIA to IIIB patients and met both of its dual primary endpoints, with median event-free survival of 47.2 months compared to 18.3 months with placebo, and a clear overall survival advantage. Despite lingering debates over whether patients who achieve a complete pathological response still need postoperative immunotherapy, neoadjuvant chemoimmunotherapy is now firmly embedded in clinical practice.

What distinguishes this report is the effort to understand why this particular patient responded so completely, and the investigators approached that question from several angles simultaneously. Baseline immunohistochemistry using the Dako 22C3 assay showed a tumor proportion score for PD-L1 of just 5 percent, a level generally considered low and, on its own, a poor predictor of benefit from checkpoint blockade. That finding underscores a persistent problem in the field: PD-L1 expression alone fails to capture the complexity of immunotherapy response, particularly in squamous histology, where the immune landscape differs markedly from that of lung adenocarcinoma. Previous work has shown that lung squamous cell carcinoma carries a predominantly immunocompromised signature, including heavy infiltration of M2-polarized macrophages into tumor islets and downregulation of complement cascade genes.

To probe that microenvironment directly, the team employed multiplex immunofluorescence on baseline and post-treatment specimens, using DAPI to label all cell nuclei, pan-cytokeratin to mark cancer cells, CD68 as a pan-macrophage marker, CD86 and IRF5 to identify pro-inflammatory M1 macrophages, and CD163 and CD206 to flag immunosuppressive M2 macrophages. The results painted a picture of an immune landscape tilted toward tumor promotion. In the baseline primary tumor, M1 cells numbered 11 per square millimeter while M2 cells reached 77 per square millimeter. After treatment, the resected tumor bed showed a single M1 cell against 103 M2 cells per square millimeter, yet the resected lymph node told a different story, with the M1-to-M2 density gap narrowing to a difference of 22 per square millimeter compared to 102 in the tumor bed. The authors interpret the lymph node finding as evidence of a pro-anti-tumor environment in the tumor-draining lymph nodes, consistent with the favorable clinical outcome. Preclinical studies support this reading: anti-PD-L1 antibodies have been shown to remodel the macrophage compartment toward a more proinflammatory phenotype through interferon-gamma signaling, and sugemalimab specifically has been reported to upregulate M1 macrophages while suppressing myeloid-derived suppressor cells.

The investigators also examined the immunoproteasome, a specialized form of the proteasome complex whose catalytic subunits PSMB-8, PSMB-9, and PSMB-10 are induced by interferon-gamma and tumor necrosis factor-alpha under inflammatory conditions and are implicated in antigen presentation, tumor invasion, and lymph node metastasis. Using quantitative H-score analysis with QuPath software, they found that expression of all three subunits peaked in the resected lymph node samples. PSMB-8 scored 195 in the primary lesion, 239 in the lymph node, and 191 in the tumor bed; PSMB-9 scored 145, 155, and 126 respectively; and PSMB-10 scored 181, 200, and 197. When binned into low, intermediate, and high categories, PSMB-9 and PSMB-10 expression proved broadly similar across the three sites, with only PSMB-10 appearing meaningfully elevated in the lymph nodes. The authors caution that a single case cannot establish mechanism, but they suggest that PSMB-8 inhibition and its relationship to anti-tumor outcomes in tumor-draining lymph nodes merit systematic exploration.

Perhaps the most clinically translatable finding came from the liquid biopsy. Using next-generation sequencing targeting 425 tumor-related genes on plasma samples collected before treatment and after one cycle of neoadjuvant therapy, the team measured a baseline tumor mutational burden of 4.1 mutations per megabase with six detectable somatic mutations. After a single cycle of chemoimmunotherapy, circulating tumor DNA fell to zero, a complete molecular clearance that preceded both the radiographic response and the pathological one. Circulating tumor DNA has emerged as a promising non-invasive marker of molecular residual disease, capable of signaling recurrence or metastasis before standard imaging can detect it. In this case, the early clearance complemented the imaging assessment as a predictor of treatment response, and the authors argue that ctDNA surveillance could eventually help determine which patients with complete pathological responses can safely forgo or shorten adjuvant therapy, a question that remains unresolved.

The report’s authors, led by Ziyi Xu and Puyuan Xing of the National Cancer Center in Beijing, are careful to frame the findings appropriately. A single patient cannot prove that sugemalimab plus chemotherapy is superior to alternatives, and the biomarker observations, from macrophage polarization to immunoproteasome expression, are hypothesis-generating rather than definitive. Yet the case illustrates a broader convergence in oncology: treatment decisions increasingly informed not just by what a tumor looks like under the microscope, but by the molecular conversation it conducts with the immune system. The patient, a heavy smoker with a 30-pack-year history whose tumor expressed low levels of PD-L1, would have been difficult to flag as a responder using any single conventional marker. It was the combination of pathological response, molecular clearance in the blood, and microenvironmental shifts across three tissue compartments that revealed the depth of the treatment effect. As the investigators note, PD-L1 status, circulating tumor DNA dynamics, and tumor microenvironment characteristics together form a set of hallmark features indicative of clinical outcomes, and larger prospective studies will be needed to determine which of these signals can reliably guide therapy for the many stage IIIB patients whose tumors remain stubbornly inoperable.

Subject of Research: Neoadjuvant anti-PD-L1 immunotherapy combined with chemotherapy for stage IIIB lung squamous cell carcinoma and associated predictive biomarkers

Article Title: Case report of neoadjuvant treatment with sugemalimab combined with platinum-based doublet chemotherapy in stage IIIB lung squamous cell carcinoma and research in potential biomarkers

Article References: Xu, Z., Chen, D., Xie, T., Shao, K., Li, Y., Ying, J., Li, J., & Xing, P. (2026). Case report of neoadjuvant treatment with sugemalimab combined with platinum-based doublet chemotherapy in stage IIIB lung squamous cell carcinoma and research in potential biomarkers. Heliyon, 12(15), Article e45473. https://doi.org/10.1016/j.heliyon.2026.e45473

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45473

Keywords: lung squamous cell carcinoma, sugemalimab, neoadjuvant chemoimmunotherapy, pathological complete response, PD-L1, circulating tumor DNA, tumor mutational burden, tumor microenvironment, macrophage polarization, immunoproteasome, non-small cell lung cancer, biomarkers

The research began with a deceptively simple question: which cells inside a head and neck tumor are actually burning LDL cholesterol? Using single-cell RNA sequencing, the team scored every cell in the tumor microenvironment for the activity of LDL-related metabolic genes. The answer was striking. Rather than the cancer cells themselves, it was the myeloid compartment, the family of innate immune cells that includes monocytes, dendritic cells, and macrophages, that showed the highest LDL metabolic activity. Within that compartment, macrophages stood out as the most metabolically active population, suggesting that these scavenger cells, which are known to engulf lipids and cellular debris, are the primary consumers of cholesterol traffic inside the tumor.

This finding matters because macrophages are not passive bystanders. Depending on the signals they receive, they can either rally anti-tumor immune responses or actively suppress them, and their metabolic state is increasingly understood to dictate which behavior dominates. The researchers went a step further and dissected the macrophage population into subtypes, uncovering a subset defined by expression of the secreted protein SPP1, also known as osteopontin. These macro_SPP1 macrophages displayed a double dose of pathological activity: heightened LDL metabolism and elevated extracellular matrix remodeling, two processes closely linked to tumor invasion and fibrosis. Critically, this subset also showed upregulation of ITGA5, the gene encoding integrin alpha 5, a cell-surface receptor subunit that anchors cells to fibronectin in the extracellular matrix.

To translate these single-cell observations into something clinically useful, the team built a machine learning-based prognostic model centered on LDL metabolism-associated genes. When applied to independent validation datasets, the model reliably stratified head and neck squamous cell carcinoma patients into high-risk and low-risk groups with significantly different overall survival. The stratification held up in multivariate Cox regression analyses that accounted for standard clinical variables such as tumor stage, nodal status, and grade, indicating that the LDL metabolic signature carries prognostic information beyond what clinicians already measure. Receiver operating characteristic analysis and concordance index calculations confirmed that the model’s predictive performance was robust across cohorts.

Perhaps the most provocative results emerged when the researchers overlaid the risk score onto immunotherapy data. In an independent cohort of patients treated with immune checkpoint blockade, high-risk patients responded more poorly to therapy. The high-risk group also exhibited a distinctive immune landscape: elevated tumor mutational burden, which in many cancer types predicts better immunotherapy outcomes, but simultaneously reduced immune cell infiltration into the tumor. This paradoxical combination, a genetically noisy tumor that somehow keeps immune cells at arm’s length, is precisely the scenario in which checkpoint inhibitors often fail, and it suggests that LDL metabolic reprogramming may be one of the mechanisms by which tumors construct an immunologically cold microenvironment despite carrying abundant mutations for the immune system to recognize.

The team then turned to spatial transcriptomics to verify that these molecular patterns correspond to actual geography within tissue. The technique, which preserves the physical layout of cells while reading their gene expression, confirmed that ITGA5 was enriched in tumor regions with high LDL metabolic activity. This spatial concordance is important because it rules out the possibility that the single-cell findings were artifacts of cell dissociation, and it places the ITGA5-LDL axis squarely within the tumor proper rather than the surrounding stroma. Correlation analyses in both bulk transcriptomic datasets and single-cell data reinforced the link, showing that ITGA5 expression tracks with canonical cholesterol metabolism genes including LDLR, SQLE, and SOAT1 across multiple independent cohorts.

To test whether ITGA5 is merely a bystander marker or an active driver of malignancy, the researchers performed functional experiments in head and neck cancer cell lines. When ITGA5 expression was knocked down using short hairpin RNA, the cells lost key malignant capabilities: proliferation measured by CCK-8 and EdU assays declined, and both migration and invasion were impaired. Conversely, the survival analysis showed that patients with low ITGA5 expression had more favorable clinical outcomes. Intriguingly, treatment of HN-5 and UMSCC-47 cells with LDL or oxidized LDL modulated the expression of ITGA5 and several macrophage-associated lipid genes including SPP1, TREM2, APOE, and LPL, hinting at a biochemical conversation between circulating lipids and the tumor’s transcriptional state.

The study also explored what distinguishes ITGA5-high from ITGA5-low macrophages within the macro_SPP1 subset. Gene set enrichment analysis revealed that the ITGA5-high macrophages were enriched for pathways including epithelial-mesenchymal transition, TNF/NF-kappaB signaling, hypoxia, glycolysis, mTORC1 signaling, and interferon-gamma response, while showing alterations in oxidative phosphorylation and antigen processing and presentation. This transcriptional profile paints a picture of macrophages that are metabolically rewired, pro-inflammatory in a potentially tumor-promoting way, and less capable of properly presenting antigen to T cells, a combination that would be expected to blunt anti-tumor immunity while supporting tissue invasion and matrix remodeling.

Taken together, the findings establish LDL metabolic reprogramming as a feature of head and neck squamous cell carcinoma that operates on two fronts simultaneously. In the immune compartment, it defines a macrophage state associated with matrix destruction and immunosuppression; in the malignant compartment, ITGA5 acts as a tumor cell-intrinsic effector that directly promotes proliferation, migration, and invasion. The dual role is unusual and clinically meaningful, because it suggests that a single metabolic axis could be targeted to influence both the cancer cells and the immune cells that surround them. The prognostic model developed from this axis could, in principle, help clinicians identify patients unlikely to benefit from immune checkpoint blockade and direct them toward alternative or combination strategies.

As with any multi-omics study, important caveats remain. The prognostic model was developed and validated on retrospective datasets, and prospective clinical validation would be needed before the risk score could guide treatment decisions. The functional experiments, while convincing at the cellular level, do not yet establish whether manipulating LDL metabolism in patients would alter tumor behavior, and the relationship between dietary or pharmacological cholesterol management and cancer outcomes remains an open question. Nevertheless, by demonstrating that a metabolic pathway classically associated with heart disease is woven into the architecture of the head and neck tumor microenvironment, the study opens a genuinely new line of investigation. If future work confirms that targeting the ITGA5-LDL axis can reprogram macrophages and sensitize tumors to immunotherapy, the humble cholesterol particle may find an unexpected second act in oncology.

Subject of Research: LDL metabolism-associated myeloid signatures and tumor cell-intrinsic ITGA5 in head and neck squamous cell carcinoma

Article Title: Single-cell analysis identifies an LDL metabolism–associated myeloid signature and tumor cell–intrinsic ITGA5 in HNSCC

Article References: Ma, H., Wang, S., Xiong, L., Hahan, Z., Zhao, P., Wu, Y., Wei, M., & Wang, X. (2026). Single-cell analysis identifies an LDL metabolism–associated myeloid signature and tumor cell–intrinsic ITGA5 in HNSCC. BMC Cancer. https://doi.org/10.1186/s12885-026-17006-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17006-x

Keywords: head and neck squamous cell carcinoma, LDL metabolism, macrophages, single-cell RNA sequencing, ITGA5, tumor microenvironment, immunotherapy, tumor mutational burden, spatial transcriptomics, cholesterol metabolism, prognostic model, SPP1 macrophages